{"id":127867,"date":"2026-09-08T21:55:45","date_gmt":"2026-09-08T21:55:45","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/127867\/"},"modified":"2026-09-08T21:55:45","modified_gmt":"2026-09-08T21:55:45","slug":"novartis-dm1-drug-misses-primary-endpoint-in-phase-iii-trial","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/127867\/","title":{"rendered":"Novartis DM1 Drug Misses Primary Endpoint in Phase III Trial"},"content":{"rendered":"<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/51997b89f5a160d89535ca09681b79fc51446e8440130b54d27c9b22ae6ea2cb\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Finvestorshub_458%2F9e4022443fc0ce16c22c06e42f430cd6.png\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Medical research testing sample \u00a9StockMix\" height=\"527\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> Medical research testing sample \u00a9StockMix           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis (NYSE:NVS) said on Tuesday that its experimental treatment for myotonic dystrophy type 1, delpacibart etedesiran, did not meet the primary endpoint of a Phase III clinical trial.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The global HARBOR study evaluated delpacibart etedesiran, also known as del-desiran, in approximately 150 people with myotonic dystrophy type 1, or DM1.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The 54-week randomised, double-blind and placebo-controlled study did not demonstrate a statistically significant improvement compared with placebo in video hand opening time, the trial&#8217;s primary endpoint and a measure of hand muscle stiffness.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis said the study showed evidence of clinical activity on other measures and in additional analyses. Safety findings were generally consistent with previously reported data.  <\/p>\n<p>        Novartis to Review HARBOR Trial Data          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The company said it will evaluate the complete dataset and engage with health authorities to determine the appropriate development path for del-desiran.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;Despite decades of research, there are still no approved treatment options for DM1, and patients and caregivers continue to face a significant daily burden,&#8221; said Shreeram Aradhye, Novartis&#8217;s president of development and chief medical officer.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;Developing therapies for a complex disease like DM1 remains challenging, and setbacks are part of scientific progress.&#8221;  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">DM1 is a progressive neuromuscular disease caused by an expansion of CTG repeats, which are repeated sections of DNA, in the DM1 protein kinase gene.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Del-desiran is an antibody oligonucleotide conjugate designed to target and break down disease-causing DMPK messenger RNA.  <\/p>\n<p>        Del-desiran Holds FDA and EU Designations          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Del-desiran has received Orphan Drug, Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration. It also has Orphan Medicinal Product designation in the European Union.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The treatment is one of three antibody oligonucleotide conjugate therapies added to Novartis&#8217;s neuromuscular pipeline through its acquisition of Avidity Biosciences.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Another candidate, delpacibart zotadirsen, has been submitted for accelerated FDA approval for Duchenne muscular dystrophy involving mutations amenable to exon 44 skipping and has received priority review designation.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis also plans to meet with the FDA to discuss the next steps for delpacibart braxlosiran in facioscapulohumeral muscular dystrophy, based on positive Phase I\/II biomarker data.  <\/p>\n<p>            Novartis Maintains Five-Year Sales Guidance           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Despite the HARBOR trial result, Novartis maintained its existing five-year sales outlook.  <\/p>\n","protected":false},"excerpt":{"rendered":"Medical research testing sample \u00a9StockMix Novartis (NYSE:NVS) said on Tuesday that its experimental treatment for myotonic dystrophy type&hellip;\n","protected":false},"author":2,"featured_media":127868,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[62206,62371,62370,62249,206,30855,42194,10447,6650],"class_list":["post-127867","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-dm1","tag-experimental-treatment","tag-global-harbor","tag-myotonic-dystrophy-type-1","tag-novartis","tag-novartis-stock-price","tag-orphan-drug","tag-phase-iii-clinical-trial","tag-primary-endpoint"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117237653575739013","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/127867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=127867"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/127867\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/127868"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=127867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=127867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=127867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}